Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. ('Alto') (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the identification of a patient selection biomarker and positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept (POC) trial of ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. ALTO-203 is a novel, oral, histamine H3 inverse agonist, designed to modulate circuits underlying cognition, wakefulness, and alertness.
The profile exhibited by ALTO-203 in the exploratory POC trial demonstrated clear effects on objective measures of attention and wakefulness, with observed improvements linked to changes in the EEG theta/beta ratio—a biomarker indexing cortical arousal and attentional control. These findings replicate results from the Phase 1 study in healthy volunteers, where ALTO-203 treatment led to improvements in sustained attention and reductions in the EEG theta/beta ratio. Baseline EEG theta/beta ratio predicted attentional benefits of ALTO-203 in both the Phase 1 study and Phase 2 POC trial.
'We aim to leverage objective biomarkers to enable targeted neuropsychiatric drug development so that patients can get better, faster,' said Amit Etkin, M.D., Ph.D., founder and CEO of Alto Neuroscience. 'In this exploratory trial, we identified a robust biomarker for ALTO-203, EEG high-theta/beta ratio, which is a well-validated measure of abnormal cortical arousal and poor attentional control. Notably, this biomarker is FDA-cleared for use alongside clinical evaluation in the diagnosis of ADHD, reinforcing its clinical relevance. These positive results replicate findings from an ALTO-203 Phase 1 study and enhance our understanding of the patient subtypes most likely to benefit from the drug, further strengthening the foundation of our precision psychiatry approach. We believe our platform has the potential to enable data-driven indication selection and trial design early in development—accelerating the path to more effective, personalized treatment.'
The exploratory Phase 2 POC trial, which enrolled 69 patients, was conducted in two sequential, double-blind, placebo-controlled periods. The trial was designed to characterize the pharmacodynamic, pharmacokinetic, safety, and tolerability profile of ALTO-203 across two dose levels compared to placebo in a crossover design and was not powered to detect statistical significance on traditional depression outcome scales (e.g., MADRS).
Adam Savitz, M.D., Ph.D., Chief Medical Officer of Alto Neuroscience, commented, 'We are encouraged by the positive pharmacodynamic activity observed in the study, which aligns with the proposed mechanism of ALTO-203. The wake-promoting and pro-cognitive effects demonstrated, suggest clear potential for ALTO-203 to be a meaningful treatment across various neuropsychiatric conditions in which sleep and attention are significantly impaired.'
Topline, prespecified results from the exploratory Phase 2 POC trial of ALTO-203 include:
Subjective Effects on Bond & Lader Visual Analog Scale (BL-VAS): Patients reported significant improvements from baseline on BL-VAS for alertness & mood at the 5-hour timepoint post dosing with ALTO-203. A higher-than-expected placebo response was observed on the Bond & Lader measurements – no significant separation between ALTO-203 and placebo was observed.
EEG Biomarker of Drug Effect Identified: The theta/beta ratio, a neurophysiological marker linked to attentional control, was confirmed as a key pharmacodynamic readout. The effects of ALTO-203 on reducing theta/beta ratio were significant compared to placebo (25µg: p<0.05).
This marker was previously shown to be significantly reduced by ALTO-203 in the completed Phase 1 study in healthy subjects, as well as in preclinical studies.
Cognitive Enhancement Observed: ALTO-203 treatment led to significant improvements in sustained attention (25µg: p<0.05; 75µg: p=0.06 vs. placebo), aligning with reductions in the EEG theta/beta ratio. Improvement in attention was greatest in patients with high baseline theta/beta ratios (i.e., more abnormal) (25µg: p<0.01; 75µg: p<0.05 vs. placebo).
The observed improvements in attention and corresponding changes in EEG theta/beta ratio replicated significant findings from the Phase 1 study.
Wearable Device Confirmation: Objective sleep measures from wearable devices supported the wake-promoting effects of ALTO-203, and the increased wakefulness exhibited by ALTO-203 was significant for both doses (25µg: p<0.05; 75µg: p<0.001 vs. placebo).
Pharmacokinetics and Safety: ALTO-203 displayed predictable accumulation over multiple doses with no adverse pharmacokinetic signals. ALTO-203 was well tolerated, with insomnia as the most frequent adverse event, consistent with its wake-promoting profile.
MADRS Improvements: Patients taking 25µg of ALTO-203 exhibited a mean improvement of 2 points at week 3 and 0.9 points at week 4 compared to placebo. The differences were not observed in the 75µg dose group.
MADRS improvements were evaluated during the 28-day multi-dose period, which was not powered to detect significance.
Alto plans to report additional results from this exploratory study at a future medical meeting and expects to determine the next development steps for ALTO-203 following the complete analysis of the data set.
About the Phase 2 POC Trial of ALTO-203
The Phase 2 POC trial enrolled 69 MDD patients with higher levels of anhedonia consisted of two dosing periods (63 completed the primary single-dose period):
Single-dose period: Patients received two single-doses of ALTO-203 (25µg and 75µg), and placebo in a randomized, three-way crossover design. The powered primary outcome was an acute change in positive emotion assessed by the alertness and mood components of the Bond-Lader Visual Analog Scale (BL-VAS), an established scale of subjective feelings. Key pre-specified exploratory outcomes included measures of cognition, EEG changes, and effects on sleep.
Multi-dose period: Patients were randomized to receive daily administration of ALTO-203 (25µg or 75µg QD) or placebo over 28 days. This period was designed to evaluate extended safety, tolerability, and pharmacokinetics, as well as exploratory biomarkers across EEG, cognitive testing, and wearable device data.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto's clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as 'expects,' 'plans,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto's expectations about the potential benefits, activity, effectiveness and safety of its product candidates and Precision Psychiatry Platform ('Platform'); the reproducibility of any favorable results seen in the exploratory Phase 2 POC trial of ALTO-203 in major depressive disorder; and Alto's expectations with regard to the design and results of its clinical trials. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials and other important factors, any of which could cause Alto's actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled 'Risk Factors' in Alto's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.
Availability of Information on Alto's Website
Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
25 minutes ago
- Business Upturn
QuantumScape shares surge 54% in two days as manufacturing breakthrough fuels investor optimism
By Aditya Bhagchandani Published on June 26, 2025, 20:08 IST Shares of QuantumScape Corporation (NYSE: QS) continued their remarkable rally on Thursday, June 26, rising nearly 19% to $6.80, following a 35% surge on Wednesday. The two-day rally marks a staggering 54% gain, driven by investor enthusiasm after the company announced a major breakthrough in its manufacturing process for solid-state lithium-metal batteries. On Tuesday, QuantumScape revealed that its Cobra ceramic separator process has now become the new standard for its battery cell production lines. The company said Cobra significantly accelerates production throughput—processing battery cell components 25 times faster than earlier methods while requiring only a fraction of the equipment footprint. This development is expected to lay the foundation for QuantumScape to scale up to gigafactory-level production capacity. CEO Siva Sivaram highlighted that Cobra will enable faster manufacturing, better battery life, shorter charging times, and reduced production costs. Solid-state batteries are considered the future of electric vehicle (EV) power sources, offering higher energy density and faster charging times compared to conventional lithium-ion batteries. The announcement holds strategic importance for Volkswagen, which owns a 24% stake in QuantumScape and has invested $380 million in the startup since 2012. Volkswagen recently signed a deal to license QuantumScape's manufacturing technology for mass production of solid-state batteries. QuantumScape also stated that it has entered sampling agreements with other original equipment manufacturers (OEMs), including both mainstream and luxury automakers, signaling growing commercial interest. The surge comes despite the stock being down over 40% over the last five years, even with this week's jump. Analysts say this breakthrough could reinvigorate investor sentiment and renew optimism about QuantumScape's long-term potential in the EV battery market. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
San Francisco Chronicle
27 minutes ago
- San Francisco Chronicle
How to manage ADHD at work and turn it into a strength
NEW YORK (AP) — Jeremy Didier had taken her son to a psychologist for a possible ADHD evaluation when she spotted an article about women with the condition. As she read it in the waiting room, she thought to herself: They're describing me. 'Lots of risk-taking, lots of very impulsive behavior growing up,' Didier said. As the magazine described, she'd excelled in school but gotten in trouble for talking too much. She'd amassed too many speeding tickets as an adult. She turned to her husband and said, "I think I might have ADHD.' Didier is now the board president of Children and Adults with Attention-Deficit/Hyperactivity Disorder, a nonprofit advocacy and support organization. Her realization mirrors the experiences of other adults who wonder if they have ADHD after a child's diagnosis. Attention-deficit/hyperactivity disorder is a neurodevelopmental condition characterized by inattention, hyperactivity or a combination of the two. Common symptoms such as trouble concentrating or sitting still can create challenges at work. People with ADHD are often passed over for promotions, said Andrew Sylvester, a psychiatrist at UCHealth, a hospital in Longmont, Colorado. Difficulties with attention may lead the mind to drift during meetings, and cause someone to miss important discussion nuances. The disorder may interfere with organization, planning and remembering details. Yet some adults think of having ADHD as a source of personality strengths and ways of thinking that benefit employers. Diagnostic manuals may call it a disorder, but it also can be a superpower, they said. 'Our brains work differently and so we're more likely to be able to think outside the box and come up with different things, and sometimes that's because we've had to do that in order to to survive,' Didier said. Finding community Getting diagnosed with ADHD doesn't always lead to a quick fix. While doctors often recommend medication and therapy, not everyone can take medication, and those routes don't necessarily eliminate all symptoms. Didier floundered with a messy house and lots of yelling as she and four of her five children were diagnosed with ADHD. She experimented with medicine, diets and reward charts, and discovered what helped her the most: a community of parents who had children with ADHD. 'There's nothing like talking to other people who are going through what you're going through to help you feel ... that you're not alone,' she said. Didier eventually became a social worker and now runs support groups for adults with ADHD, teaching skills they can use at work. Some organizations have employee resource groups organized around neurodiversity to provide camaraderie and support to adults with ADHD, autism, dyslexia and other conditions. GPS of the brain People with ADHD often struggle with executive function, which Didier describes as 'your brain's GPS' for navigating your day. Executive function is a set of mental skills that includes making plans, managing time and flexible thinking. It also includes working memory, which helps us keep track of what we're doing. To keep from getting derailed, experts recommend breaking large tasks into chunks, writing detailed to-do lists and taking breaks. Personal chef Bill Collins, 66, who was diagnosed with ADHD two years ago, writes structured lists when he's making a meal for a client. He creates categories for kitchen areas — counter, stove and oven — and then lists tasks such as 'chop carrots, boil water for pasta' underneath each category. Then he numbers each task so he knows exactly what to do, where and when. 'That's how I got around my unknown ADHD early on, just making lists,' Collins said. 'If it's something I don't want to do, I put it at the top of the list so I can be done with it." Another technique is called 'body doubling,' which involves a pair of work colleagues meeting over Zoom or in-person to focus on completing projects. The two may choose to perform separate tasks — one might build a presentation deck while the other files tax reports — but help each other stay accountable. 'You're just sitting there during that dedicated time, getting things done,' Didier said. Insurance company Liberty Mutual provides an AI tool that helps break down large projects into manageable tasks and provides reminders about deadlines, to help employees with ADHD stay focused and organized, said Head of Benefits Verlinda DiMarino. Getting through meetings Meetings can be difficult for people with ADHD if their minds drift or they feel an urge to get up out of a chair. They also may struggle with impulse control and find it hard to wait their turn to speak. Nicole Clark, CEO of the Adult and Pediatric Institute, a mental health practice in Stuart, Florida, suggests asking for meeting topics in advance and writing up talking points. If you think of questions during the meeting, write them down. Some employers use a voice-to-text service, projecting what a speaker is saying on a screen, which helps people with attention difficulties stay focused, Clark said. Sylvester, the psychiatrist, recommends practicing active listening by repeating in your head what someone just said, or taking a brief time-out from a meeting to reset. Tell them, ''I need five minutes. I'll be right back.' Get up and walk out. Do what you need to do,' he said. Mariel Paralitici-Morales, chief medical officer of the Adult and Pediatric Institute, who has ADHD, sits close to whoever will be speaking to help sustain attention. 'Having something in my hand helps,' said Paralitici-Morales, who sometimes holds a fidget spinner. 'If we have to talk, I found it's easier for me to be the first one and break the ice" to keep herself from second-guessing what she planned to say. Seek accommodations People with an ADHD diagnosis can request accommodations at work through the Americans with Disabilities Act. Noise-canceling headphones may help. Consider asking for the ability to take a break every 20 minutes, Sylvester said. 'Set a timer for five to 10 minutes. Get up and walk around. Make some coffee. Go play with the dog,' he said. 'When that timer goes off, go back to a 15 to 20 minute hard productivity cycle.' Employees can also request a flexible schedule or ability to work from home, which can enable time for therapy or self-care. Antoinette Damico, 23, who coordinates events at an executive search firm in San Francisco, said she practices meditation, writes daily goals in a journal and stays off short-form media to improve her concentration. Celebrate your strengths Having ADHD can be an asset in the workplace, and many CEOs and entrepreneurs are neurodiverse, Didier said. 'We bring all kinds of unique talents to our workplaces. Hyper-focus, lots of energy, resilience, the ability to multitask,' she added. 'There's something about people with ADHD that seems to unmask or give us a greater capacity for creativity and innovation.' Damico also thinks her ADHD provides some advantages. When she's interested in a topic, she can be extremely focused, reading extensively and talking about the topic nonstop, a trait others with ADHD report. 'It can generate a real passion in you that is a bit unique," she said. "It really creates this grit in me in terms of when I really want to accomplish something, there's this boost of energy.' ___
Hamilton Spectator
30 minutes ago
- Hamilton Spectator
How to manage ADHD at work and turn it into a strength
NEW YORK (AP) — Jeremy Didier had taken her son to a psychologist for a possible ADHD evaluation when she spotted an article about women with the condition. As she read it in the waiting room, she thought to herself: They're describing me. 'Lots of risk-taking, lots of very impulsive behavior growing up,' Didier said. As the magazine described, she'd excelled in school but gotten in trouble for talking too much. She'd amassed too many speeding tickets as an adult. She turned to her husband and said, 'I think I might have ADHD.' Didier is now the board president of Children and Adults with Attention-Deficit/Hyperactivity Disorder, a nonprofit advocacy and support organization. Her realization mirrors the experiences of other adults who wonder if they have ADHD after a child's diagnosis. Attention-deficit/hyperactivity disorder is a neurodevelopmental condition characterized by inattention, hyperactivity or a combination of the two. Common symptoms such as trouble concentrating or sitting still can create challenges at work. People with ADHD are often passed over for promotions, said Andrew Sylvester, a psychiatrist at UCHealth, a hospital in Longmont, Colorado. Difficulties with attention may lead the mind to drift during meetings, and cause someone to miss important discussion nuances. The disorder may interfere with organization, planning and remembering details. Yet some adults think of having ADHD as a source of personality strengths and ways of thinking that benefit employers. Diagnostic manuals may call it a disorder, but it also can be a superpower, they said. 'Our brains work differently and so we're more likely to be able to think outside the box and come up with different things, and sometimes that's because we've had to do that in order to to survive,' Didier said. Here are some ways to cope with and channel ADHD in the workplace. Finding community Getting diagnosed with ADHD doesn't always lead to a quick fix. While doctors often recommend medication and therapy, not everyone can take medication , and those routes don't necessarily eliminate all symptoms. Didier floundered with a messy house and lots of yelling as she and four of her five children were diagnosed with ADHD. She experimented with medicine, diets and reward charts, and discovered what helped her the most: a community of parents who had children with ADHD. 'There's nothing like talking to other people who are going through what you're going through to help you feel ... that you're not alone,' she said. Didier eventually became a social worker and now runs support groups for adults with ADHD, teaching skills they can use at work. Some organizations have employee resource groups organized around neurodiversity to provide camaraderie and support to adults with ADHD, autism, dyslexia and other conditions. GPS of the brain People with ADHD often struggle with executive function, which Didier describes as 'your brain's GPS' for navigating your day. Executive function is a set of mental skills that includes making plans, managing time and flexible thinking. It also includes working memory, which helps us keep track of what we're doing. To keep from getting derailed, experts recommend breaking large tasks into chunks, writing detailed to-do lists and taking breaks. Personal chef Bill Collins, 66, who was diagnosed with ADHD two years ago, writes structured lists when he's making a meal for a client. He creates categories for kitchen areas — counter, stove and oven — and then lists tasks such as 'chop carrots, boil water for pasta' underneath each category. Then he numbers each task so he knows exactly what to do, where and when. 'That's how I got around my unknown ADHD early on, just making lists,' Collins said. 'If it's something I don't want to do, I put it at the top of the list so I can be done with it.' Another technique is called 'body doubling,' which involves a pair of work colleagues meeting over Zoom or in-person to focus on completing projects. The two may choose to perform separate tasks — one might build a presentation deck while the other files tax reports — but help each other stay accountable. 'You're just sitting there during that dedicated time, getting things done,' Didier said. Insurance company Liberty Mutual provides an AI tool that helps break down large projects into manageable tasks and provides reminders about deadlines, to help employees with ADHD stay focused and organized, said Head of Benefits Verlinda DiMarino. Getting through meetings Meetings can be difficult for people with ADHD if their minds drift or they feel an urge to get up out of a chair. They also may struggle with impulse control and find it hard to wait their turn to speak. Nicole Clark, CEO of the Adult and Pediatric Institute, a mental health practice in Stuart, Florida, suggests asking for meeting topics in advance and writing up talking points. If you think of questions during the meeting, write them down. Some employers use a voice-to-text service, projecting what a speaker is saying on a screen, which helps people with attention difficulties stay focused, Clark said. Sylvester, the psychiatrist, recommends practicing active listening by repeating in your head what someone just said, or taking a brief time-out from a meeting to reset. Tell them, ''I need five minutes. I'll be right back.' Get up and walk out. Do what you need to do,' he said. Mariel Paralitici-Morales, chief medical officer of the Adult and Pediatric Institute, who has ADHD, sits close to whoever will be speaking to help sustain attention. 'Having something in my hand helps,' said Paralitici-Morales, who sometimes holds a fidget spinner. 'If we have to talk, I found it's easier for me to be the first one and break the ice' to keep herself from second-guessing what she planned to say. Seek accommodations People with an ADHD diagnosis can request accommodations at work through the Americans with Disabilities Act. Noise-canceling headphones may help. Consider asking for the ability to take a break every 20 minutes, Sylvester said. 'Set a timer for five to 10 minutes. Get up and walk around. Make some coffee. Go play with the dog,' he said. 'When that timer goes off, go back to a 15 to 20 minute hard productivity cycle.' Employees can also request a flexible schedule or ability to work from home, which can enable time for therapy or self-care. Antoinette Damico, 23, who coordinates events at an executive search firm in San Francisco, said she practices meditation, writes daily goals in a journal and stays off short-form media to improve her concentration. Celebrate your strengths Having ADHD can be an asset in the workplace, and many CEOs and entrepreneurs are neurodiverse, Didier said. 'We bring all kinds of unique talents to our workplaces. Hyper-focus, lots of energy, resilience, the ability to multitask,' she added. 'There's something about people with ADHD that seems to unmask or give us a greater capacity for creativity and innovation.' Damico also thinks her ADHD provides some advantages. When she's interested in a topic, she can be extremely focused, reading extensively and talking about the topic nonstop, a trait others with ADHD report. 'It can generate a real passion in you that is a bit unique,' she said. 'It really creates this grit in me in terms of when I really want to accomplish something, there's this boost of energy.' ___ Share your stories and questions about workplace wellness at cbussewitz@ . Follow AP's Be Well coverage, focusing on wellness, fitness, diet and mental health at
